CLAIMS

1. An injectable pharmaceutical formulation comprising:
   (a) an effective amount of linezolid,
   (b) a thermosensitive hydrogel comprising poloxamer and iohexol, and optionally
   (c) at least one pharmaceutically acceptable excipient,
   wherein linezolid forms a suspension in the thermosensitive hydrogel.

2. The injectable pharmaceutical formulation of claim 1, wherein linezolid is linezolid Form II and wherein the concentration of linezolid is about 1% to about 20% by weight of the formulation.

3. The injectable pharmaceutical formulation of claim 2, wherein the poloxamer is poloxamer 407 and wherein said poloxamer 407 is present from about 9.5% to about 17% by weight of the formulation or from about 10.8% to about 12.8% by weight of the formulation.

4. The injectable pharmaceutical formulation of any of claims 1-3, wherein iohexol is present from about 14% to about 59% by weight of the formulation or from about 17% to about 30% by weight of the formulation.

5. The injectable pharmaceutical formulation of any of claims 1-4, wherein the suspension gels at a temperature from about 26°C to about 38°C such as a temperature from about 32°C to about 36°C or from about 26°C to about 32°C.

6. An injectable pharmaceutical formulation comprising about 2.5 to 20% linezolid form II, about 17% to 30% iohexol, and about 10.8% to 12.8% poloxamer by weight of the formulation.

7. The injectable pharmaceutical formulation of any of claims 1-6, wherein the injectable pharmaceutical formulation is prepared for administering to an intervertebral disc, intervertebral space, intra-articular space, site adjacent to bone edema, ligament, bone, joint, tendon, or tendon and bone junction.

8. The injectable pharmaceutical composition of claim 7, wherein the bone, joint, ligament or tendon is a bone, joint, ligament, or tendon associated with the spine.

9. The injectable pharmaceutical composition of claim 8, wherein the bone, joint, ligament, or tendon associated with the spine is associated with a cervical, thoracic, lumbar or sacral vertebra.

10. An injectable linezolid formulation comprising:
(a) a linezolid Form II powder,
(b) a thermosensitive hydrogel comprising poloxamer 407 and iohexol, and optionally
(c) at least one excipient,
wherein said linezolid formulation is prepared through the method comprising:
(i) milling linezolid form II to a defined powder,
(ii) preparing a unit of linezolid powder from step (i) and sterilizing the preparation,
(iii) preparing and sterilizing the thermosensitive hydrogel comprising poloxamer 407 and iohexol, and
(iv) suspending said linezolid powder from step (ii) in the thermosensitive hydrogel from step (iii).

11. The injectable linezolid formulation of claim 10, wherein the linezolid powder is sterilized by gamma irradiation.

12. The injectable linezolid formulation of claim 11, wherein the steps (iii) and (iv) are performed at a lower temperature than the steps (i) and (ii).

13. Use of the injectable pharmaceutical composition of any of claims 1-12, in the manufacture of a medicament for the treatment of lower back pain in a subject, wherein the medicament is to be administered via injection to the subject.

14. The use of claim 13, wherein the lower back pain is acute pain, sub-acute pain, chronic pain, local pain, radicular pain, referred pain, lumbar or cervical pain.

15. The use of claim 14, wherein the lower back pain is lumbar or cervical pain, and wherein the lumbar or cervical pain is associated with Modic changes or bone edema.

16. The use of claim 15, wherein the subject is suspected of, or has, a bacterial infection.

17. The use of claim 15, wherein the medicament is to be injected into an intervertebral disc, intervertebral space, intra-articular space, ligament, tendon, tendon and bone junction, or site adjacent to bone edema of the subject.

18. Use of the injectable pharmaceutical composition of any of claims 1-12, in the manufacture of a medicament for the treatment of pain and a bacterial infection in a cervical, thoracic, lumbar or sacral vertebra of a subject, wherein the composition is to be administered via injection into the subject in an area in, near or around the infected vertebrae.

19. A kit comprising:
    (a) a linezolid Form II powder, and
    (b) a thermosensitive hydrogel comprising poloxamer 407 and iohexol;
    wherein the kit may optionally further comprise a syringe and a needle for injection.

20. A thermosensitive hydrogel for drug delivery comprising:
    (a) poloxamer 407 which is present in the hydrogel at a concentration of about 10% to about 17% by weight of the hydrogel; and
    (b) Iohexol which is present in the hydrogel at a concentration of about 14.5% to about 62.5% by weight of the hydrogel,
    wherein the hydrogel forms gel at a temperature between 26ºC and 36ºC.